石药集团(01093.HK):SYS6043(B7-H3 ADC)用于治疗晚期乳腺癌的I/II期临床研究结果于2026年ESMO年会以快速口头报告形式公布

智通财经
Yesterday
【石药集团(01093.HK):SYS6043(B7-H3 ADC)用于治疗晚期乳腺癌的I/II期临床研究结果于2026年ESMO年会以快速口头报告形式公布】智通财经APP讯,石药集团(01093.HK)发布公告,由本集团自主研发的新型B7同源体3(B7-H3)靶向抗体偶联药物(ADC)SYS6043用于晚期乳腺癌患者的I/II期临床研究(该研究)结果,已于2026年10月26日在2026年欧洲肿瘤内科学会(ESMO)年会上以快速口头报告形式公布(编号:5RO)。该研究由复旦大学附属肿瘤医院王红霞教授进行汇报。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10